Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
NCT06971380
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
180
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma, Refractory to Standard Treatment
Multiple Myeloma, Relapsed
Light Chain Amyloidosis
Interventions
BIOLOGICAL:
HBI0101 CART
Sponsor
Polina Stepensky